Drug Trial Radar · NCT00160589
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
Last checked: Nov 20, 2026Latest source record: Dec 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
729
Actual
Start
Apr 2005
Primary completion
Sep 2005
Study completion Sep 2005
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)
Conditions
- Rhinitis, Allergic, Perennial
Interventions
LevocetirizineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline of T4SS (four symptoms score) over two weeks of treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.